| __timestamp | Bausch Health Companies Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 189101000 |
| Thursday, January 1, 2015 | 582800000 | 96351000 |
| Friday, January 1, 2016 | 455000000 | 95967000 |
| Sunday, January 1, 2017 | 366000000 | 112171000 |
| Monday, January 1, 2018 | 414000000 | 182257000 |
| Tuesday, January 1, 2019 | 471000000 | 336964000 |
| Wednesday, January 1, 2020 | 452000000 | 547851000 |
| Friday, January 1, 2021 | 465000000 | 693716000 |
| Saturday, January 1, 2022 | 529000000 | 891813000 |
| Sunday, January 1, 2023 | 604000000 | 1044071000 |
| Monday, January 1, 2024 | 910408000 |
Data in motion
In the competitive landscape of pharmaceuticals, innovation is key. Over the past decade, Exelixis, Inc. and Bausch Health Companies Inc. have been at the forefront of research and development (R&D) investments. From 2014 to 2023, Exelixis has shown a remarkable upward trend, increasing its R&D expenses by over 450%, reaching a peak in 2023. In contrast, Bausch Health's investment grew by approximately 145% during the same period.
Exelixis's commitment to innovation is evident, with its R&D spending surpassing Bausch Health by 73% in 2023. This strategic focus on R&D has positioned Exelixis as a leader in the industry, driving advancements in cancer treatment. Meanwhile, Bausch Health continues to invest steadily, maintaining its position in the market. As these companies continue to innovate, their R&D investments will likely shape the future of healthcare.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Exelixis, Inc.
R&D Insights: How Novartis AG and Exelixis, Inc. Allocate Funds
Comparing Innovation Spending: Amgen Inc. and Exelixis, Inc.
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Exelixis, Inc.
Research and Development Investment: Insmed Incorporated vs Exelixis, Inc.
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.